Ratnakar Securities Pvt. Ltd.

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private

BSE80.52-1.74 (-2.12 %)

PREV CLOSE ( ) 82.26

OPEN PRICE ( ) 82.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 61

TODAY'S LOW / HIGH ( )80.00 82.00

52 WK LOW / HIGH ( )63.55 129

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-12 1991

Management Info

R T Ravi - Chairman Jitendra Shah - Managing Director

Registered Office

Address Kothapalli Village,Anakapalli,Kasimkota Mandal,
Vishakhapatnam,
Andhra Pradesh-531031

Phone 040-66808040 / 9121144984

Email marketing@krebsbiochem.com / com_sec@krebsbiochem.com

Website www.krebsbiochem.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

03Jul Krebs Biochemicals & Industries infor
In Compliance with Regulation 74(5) of SEBI (Depositories and Participan..

23Jun Krebs Biochemicals & Industries inform
Krebs Biochemicals & Industries has informed that pursuant to SEBI (..

28May Krebs Biochemicals and Industries info
Pursuant to Regulation 24A of the SEBI (Listing Obligation and Disclosur..

24Mar Krebs Biochemicals & Industries inform
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of..

10Feb Krebs Biochemicals & Industries inform
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Krebs Bioche..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	-82.68	-269.39
Gross Profit	-82.53	-269.24
Operating Profit	-50.69	-143.21
Net Sales	61	433.12

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14601.10 (18.65%)	M.Cap ( in Cr)18733.05
Mankind Pharma (BSE) 2699.80 (4.72%)	M.Cap ( in Cr)111428.51
Torrent Pharma (BSE) 3407.05 (2.83%)	M.Cap ( in Cr)115310.05
Bharat Parenterals (BSE) 1498.50 (4.97%)	M.Cap ( in Cr)1032.76
Wockhardt (BSE) 1818.90 (3.54%)	M.Cap ( in Cr)29554.50

Shareholding Pattern

	PROMOTERS	72.74%
	NON-INSTITUTION	26.76%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

KREBS BIOCHEMICALS & INDUSTRIES LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES